



## Bulletin from the AGM of SelectImmune Pharma AB

**The Annual General Meeting (AGM) of SelectImmune Pharma AB was held on November 20, 2019. A summary of the resolutions taken is included below. All resolutions were unanimous.**

### **The adoption of the income statement, balance sheet and appropriation of earnings**

The AGM resolved to adopt the income statement and balance sheet in accordance with the annual accounts that were presented. The AGM resolved to appropriate the Company's earnings in accordance with the proposal from the Board of Directors in the annual accounts. In addition, the AGM resolved that no dividend would be paid for the 2018/2019 fiscal year.

### **Discharge from liability**

It was resolved to discharge the members of the Board of Directors and the CEO from liability for the period covered by the annual accounts that were presented at the meeting. Neither the members of the Board nor the CEO took part in this resolution.

### **Establishment of the number of Board members, deputy Board members and auditors, and the establishment of remuneration for the Board of Directors and the auditors**

The AGM resolved that the Board of Directors will consist of four members without deputies, and that one auditor is to be appointed without a deputy. The AGM further resolved that Board fees would total altogether at most SEK 275,000, divided as follows: The Chairman of the Board will receive no Board fees, re-elected Board members will receive SEK 100,000 and newly elected Board members SEK 75,000. It was resolved that the auditor's fees would be paid on approved account.

### **Election of Board of Directors and auditors**

It was resolved to elect Catharina Svanborg, Gabriela Godaly, Helena Lomberg and Carl-Johan Wachtmeister as members of the Board of Directors for the period until the end of the next AGM. It was also resolved to elect Catharina Svanborg as Chairman of the Board. Furthermore, it was resolved to elect the auditing company Ernst & Young AB as auditors for the period until the end of the next AGM. Ernst & Young have announced that they will appoint auditor Magnus Karlström as Auditor in Charge.

**For more information, please contact:**

Catharina Svanborg  
Chairman of the Board, SelectImmune Pharma AB  
Tel: +46 709 42 65 49  
E-mail: [catharina.svanborg@med.lu.se](mailto:catharina.svanborg@med.lu.se)

Fredrik Herslow  
CEO, SelectImmune Pharma AB  
Tel: +46 70 591 15 44  
E-mail: [fredrik.herslow@selectImmune.com](mailto:fredrik.herslow@selectImmune.com)

*SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.*